Trial reportRMD open2024
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study.
Trial report in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01491815 (A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Association between Modified Cardiometabolic Index and rheumatoid arthritis: the mediating role of phenotypic age acceleration.Clinical rheumatology · 2026Article
- Clinical and healthcare burden of difficult-to-treat rheumatoid arthritis in Japan: a retrospective cohort study.BMJ open · 2026Observational
- Investigating the Relationship Between Dietary Antioxidant Index With Anthropometric Indices, Clinical Symptoms, Inflammatory Markers, Sleep Quality and Quality of Life in Patients With Rheumatoid Arthritis: A Cross-Sectional Study.Health science reports · 2026Article
- Baseline body mass index and early functional recovery after first recorded advanced therapy in rheumatoid arthritis: a real-world cohort study.Rheumatology international · 2026Article
- Drivers of Methotrexate Polyglutamate Concentration in Erythrocytes: Insights from Immune-Mediated Inflammatory Diseases and Pediatric Acute Lymphoblastic Leukemia.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The association between bariatric surgery and incident rheumatoid arthritis.Rheumatology advances in practice · 2026Article
- What to do when the first TNF inhibitor fails in rheumatoid arthritis: stratified expert recommendations from a scoping review and Delphi consensus.Therapeutic advances in musculoskeletal disease · 2026Article
- Factors associated with left ventricular mass during disease modifying antirheumatic drug therapy in patients with rheumatoid arthritis: the Joint Heart study.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Association of BMI with radiographic incidence and progression of distal interphalangeal joint osteoarthritis in rheumatoid arthritis patients.Scientific reports · 2025Article
- A Lymphatic Perspective on Obesity and Inflammatory Arthritis: New Disease-Modifying Potential in Rheumatology.Journal of clinical medicine · 2025Article
- The impact of obesity and overweight on rheumatoid arthritis patients: real-world insights from a biologic and targeted synthetic DMARDs registry.Rheumatology international · 2025Observational
- Inflammatory markers mediate the association between alternative adiposity indices and mortality in patients with rheumatoid arthritis: data from NHANES 1999-2018.Lipids in health and disease · 2025Article
- The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index exhibits an L-shaped association with all-cause mortality in rheumatoid arthritis patients: a retrospective cohort study.BMC rheumatology · 2025Article
- In early rheumatoid arthritis, comorbidities do not explain the increased risk of failure to reach remission in patients with obesity.RMD open · 2025Article
- Beneficial Effects of Omega-3 Fatty Acids on Obesity and Related Metabolic and Chronic Inflammatory Diseases.Nutrients · 2025Review
- Association between body roundness index and osteoarthritis/rheumatoid arthritis: a cross-sectional study.Scientific reports · 2025Article
- Obesity and Chronic Inflammation: Implications for Rheumatoid Arthritis, Spondyloarthritis, and Ulcerative Colitis.Immunity, inflammation and disease · 2025Review
- The Impact of Triglycerides on Rheumatoid Arthritis: Risk Factor and Mendelian Randomization Study.Open access rheumatology : research and reviews · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 15 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological antirheumatic treatment in early rheumatoid arthritis (RA).
methodsThis report included 793 participants with untreated early RA from the randomised, longitudinal NORD-STAR trial, all of whom had their body mass index (BMI) assessed at baseline. Obesity was defined as BMI ≥30 kg/m
resultsOut of 793 people included in the present report, 161 (20%) had obesity at baseline. During follow-up, participants with baseline obesity had higher disease activity compared with those with lower BMI, despite having similar disease activity at baseline. In survival analyses, obesity was associated with a lower likelihood of achieving response to treatment during follow-up for up to 48 weeks (CDAI remission, HR 0.84, 95% CI 0.67 to 1.05; SDAI, HR 0.77, 95% CI 0.62 to 0.97; DAS28-CRP <2.6, HR 0.78, 95% CI 0.64 to 0.95). The effect of obesity on response to treatment was not influenced by the treatment arms.
conclusionIn people with untreated early RA followed up for up to 48 weeks, obesity was associated with a lower likelihood of good treatment response, irrespective of the type of randomised treatment received. TRIAL REGISTRATION NUMBER: NCT01491815.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.